Teva Pharmaceutical Industries (NYSE:TEVA) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Teva Pharmaceutical Industries (NYSE:TEVA) issued its quarterly earnings data on Wednesday. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.06), FiscalAI reports. The business had revenue of $4.14 billion for the quarter, compared to the consensus estimate of $4.02 billion. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Teva Pharmaceutical Industries’s revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.66 EPS. Teva Pharmaceutical Industries updated its FY 2026 guidance to 1.910-2.110 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

• Innovative products drove growth: AUSTEDO, UZEDY, and AJOVY delivered strong Q2 increases, prompting Teva to raise their combined 2026 revenue outlook by approximately $150 million at the midpoint. AUSTEDO revenue rose 40% globally, UZEDY 43%, and AJOVY 56% year over year.
• Teva raised its full-year 2026 revenue guidance midpoint by $75 million and reported $622 million of free cash flow, up 31% year over year. Management reaffirmed its targets of a 30% non-GAAP operating margin, net debt/EBITDA below 2x, and 80% cash conversion by 2027.
• The development pipeline is advancing, with potential submissions or launches including olanzapine LAI in late 2026, ecopipam for Tourette syndrome in 2027, and additional programs through 2030. Teva also expanded duvakitug development into hidradenitis suppurativa and fibrostenotic Crohn’s disease, while anti-IL-15 programs remain active in vitiligo and celiac disease.
• Generics revenue declined 15% year over year, primarily because of lower generic REVLIMID contributions, although management said the underlying generics business was broadly stable and biosimilars are becoming a growth platform. Teva expects biosimilar revenue to exceed its $800 million 2027 target.
• Management expects elevated AUSTEDO channel inventory to normalize over the next two quarters and warned that Q4 AUSTEDO revenue could decline year over year amid purchasing and pricing changes ahead of IRA implementation. Higher planned operating expenses, unfavorable foreign exchange, and the $724 million Emalex acquisition-related R&D charge also pressured reported profitability.

Teva Pharmaceutical Industries Stock Performance

Teva Pharmaceutical Industries stock traded up $3.05 on Wednesday, reaching $34.72. 11,147,745 shares of the stock were exchanged, compared to its average volume of 7,265,711. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries has a twelve month low of $14.99 and a twelve month high of $37.35. The firm has a fifty day moving average price of $33.19 and a two-hundred day moving average price of $32.68. The stock has a market cap of $39.92 billion, a PE ratio of 25.86, a PEG ratio of 3.28 and a beta of 0.86.

Insider Buying and Selling

In other news, insider Mark Sabag sold 144,180 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the transaction, the insider directly owned 80,760 shares in the company, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction dated Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares of the company’s stock, valued at $1,973,727. This represents a 34.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 465,931 shares of company stock valued at $16,332,989 in the last quarter. Insiders own 0.54% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Rubric Capital Management LP boosted its position in shares of Teva Pharmaceutical Industries by 1.8% in the second quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after acquiring an additional 450,000 shares during the period. State Street Corp increased its position in Teva Pharmaceutical Industries by 1.2% during the fourth quarter. State Street Corp now owns 17,348,809 shares of the company’s stock worth $541,456,000 after acquiring an additional 198,558 shares during the period. Duquesne Family Office LLC raised its stake in Teva Pharmaceutical Industries by 3.9% during the 3rd quarter. Duquesne Family Office LLC now owns 16,593,935 shares of the company’s stock valued at $335,197,000 after purchasing an additional 625,000 shares during the last quarter. Glenview Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 7.1% during the 2nd quarter. Glenview Capital Management LLC now owns 15,824,223 shares of the company’s stock valued at $265,214,000 after purchasing an additional 1,045,582 shares during the last quarter. Finally, Viking Global Investors LP boosted its holdings in Teva Pharmaceutical Industries by 15.4% in the 2nd quarter. Viking Global Investors LP now owns 11,681,333 shares of the company’s stock valued at $195,779,000 after purchasing an additional 1,555,855 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Innovative brands delivered strong growth. Teva reported second-quarter revenue of approximately $4.1 billion, ahead of the $4.02 billion consensus estimate. Its three key innovative brands grew 43% year over year in local-currency terms to more than $1 billion, supporting the company’s strategy of shifting its portfolio toward higher-growth products. Teva Delivers Strong Q2 Results and Raises Outlook
• Positive Sentiment: UZEDY momentum prompted a higher outlook. UZEDY U.S. sales rose 43% year over year to a record $77 million in the quarter. Teva raised its 2026 UZEDY revenue forecast to $270 million–$290 million from $250 million–$280 million, reinforcing expectations for growth from long-acting injectable treatments. UZEDY Record Q2 Net Sales and Outlook
• Positive Sentiment: Trading activity and analyst sentiment were supportive. Call-option volume was about 136% above its average daily level, indicating increased bullish speculation. Piper Sandler also raised its price target to $44 and maintained an overweight rating. The company’s broader branded-drug pipeline has further attracted investor attention.
• Neutral Sentiment: Teva raised its 2026 revenue guidance to $16.5 billion–$16.9 billion, broadly in line with the $16.7 billion consensus. The company also raised outlooks for its three key innovative brands.
• Negative Sentiment: Profitability and generics remained concerns. Quarterly EPS of $0.02 missed the $0.08 consensus, while revenue declined about 1% year over year, mainly because of lower generics sales. Full-year EPS guidance of $1.91–$2.11 is below the $2.17 analyst consensus, limiting the upside from the revenue outlook. Teva Second-Quarter Earnings Report

Analyst Ratings Changes

A number of brokerages have weighed in on TEVA. Barclays boosted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Tuesday. Truist Financial boosted their target price on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. JPMorgan Chase & Co. upped their target price on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Friday, July 17th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $42.00.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.